Tijia Fu Jiaonang (替加氟胶囊)替加氟胶囊
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 河北金砖药业有限公司Chinese legal name: 河北金砖药业有限公司
主要成分Active Ingredients
- 替加氟Tijia Fu
药物知识说明
替加氟是一种在国家药监局注册认定的药品。该药品含有替加氟-82d83c49等成分。
该药品关联的活性成分包括：替加氟Tijia Fu。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：河北金砖药业有限公司Chinese legal name: 河北金砖药业有限公司。
您可以探索含有相同成分的其他药品：替加氟-82d83c49成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 替加氟胶囊) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 替加氟Tijia Fu.
Manufacturers recorded for this product: 河北金砖药业有限公司Chinese legal name: 河北金砖药业有限公司.
Explore other medicines containing the same ingredient: 替加氟 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 替加氟胶囊Recorded Chinese name: 替加氟胶囊
- 剂型Dosage form: 胶囊剂Capsules
- 规格Specification: 0.1g0.1 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 河北金砖药业有限公司Chinese legal name: 河北金砖药业有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H13023552
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H13023552
Manufacturer
Chinese legal name: 河北金砖药业有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H13023552
生产企业
河北金砖药业有限公司(国产)
适应症
本品用于抗肿瘤药。适用于消化道肿瘤,如胃癌、结肠癌和胰腺癌,也可用于乳腺癌、支气管肺癌和原发性肝癌等。
用法用量
口服。每日0.8～1.2g,分3～4次服用,总量30～50为一疗程。小儿剂量按体重每日16～24mg/kg,分4次服用。
不良反应
1.轻度骨髓抑制表现为白细胞和血小板减少。
2.轻度胃肠道反应以食欲减退和恶心为主,个别病人可出现呕吐、腹泻和腹痛,停药后可消失。
3.其他反应有乏力、寒颤、发热、头痛、眩晕、运动失调、皮肤瘙痒、色素沉着、粘膜炎及注射部位血管疼痛等。
4.本品可引起肝、肾功能损害。
禁忌
妊娠初期3个月以内妇女禁用。对本品过敏者禁用。
注意事项
1.用药期间定期检查白细胞、血小板计数,若出现骨髓抑制,轻者对症处理,重者需减量,必要时停药。
2.轻度胃肠道反应可不必停药,给予对症处理,严重者需减量或停药,餐后服用可减轻胃肠道反应。
3.有肝肾功能障碍的病人使用时应慎重,酌情减量。
贮藏
密封保存。
规格
0.1g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.